GSK India reports FY 2025-26 results with 2% revenue growth and 10% PAT rise
Glaxosmithkline Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- Full year revenue was ₹3790 crore, up 2%; Profit After Tax increased 10% to ₹1012 crore
- EBITDA margin expanded by 290 basis points to 34%; Q4 revenue ₹989 crore, PAT ₹275 crore
- Market authorisation received for Blenrep for relapsed/refractory multiple myeloma in India
Why it's rated notable: The filing gives quarterly PAT of INR 275 crores but no year-earlier quarter figure, so the quarter's year-on-year change cannot be computed; the 10% rise to INR 1012 crores is for the full year, not the quarter, so the level stays at medium.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other dividend / buyback / bonus filings this fortnight
- Premco Global Ltd approves Q2 FY 2026-27 results, declares interim dividend, appoints auditor
- Precision Wires India board approves Sept 2026 quarter results and 35% dividend
- Dynamatic Technologies announces Q2 FY27 financial results and interim dividend
- Great Eastern Shipping approves Q2 and H1 results; declares Rs 14.40 interim dividend
- Safari Industries (India) Limited approves Q2 & H1 FY27 results, interim dividend, capex
- IRB Infrastructure Developers announces Q2 & H1 FY27 results and 2nd interim dividend
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.